News Search Results
May 27, 2026, 10:00 ET Debut and Natura Partner to Commercialize AI-Discovered Skin Longevity Ingredient for Latin America
how AI-powered biotechnology and nature-based expertise can work together across the global beauty industry.Debut The leader in biotech beauty Debut is building the future of beauty at the intersection of AI for science and biotechnology, creating high-performing
More news about: Debut Biotechnology
May 27, 2026, 09:45 ET CenExel highlights industry-leading capabilities amid growing FDA momentum advancing psychedelic clinical research
As interest in psychedelic therapies accelerates across the pharmaceutical and biotechnology industries, sponsors and CROs are increasingly looking for experienced clinical research partners capable of managing the specialized operational
More news about: CenExel Clinical Research
May 27, 2026, 09:31 ET Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
Mass., May 27, 2026 /PRNewswire/ -- Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced that it will present
More news about: Sensorium Therapeutics
May 27, 2026, 09:19 ET GBI Biomanufacturing Appoints Chandra Kelley as Chief Business Officer
planning as the company continues to expand its capabilities and market presence. Kelley brings more than 25 years of experience in the biotechnology and biopharmaceutical industry, with a proven track record of driving commercial growth, building strategic partnerships, and scaling customer-focused
More news about: GBI Biomanufacturing
May 27, 2026, 09:00 ET Ember LifeSciences announces new strategic investments boosting Series A to $27M
AMGN) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors.
More news about: Ember LifeSciences
May 27, 2026, 09:00 ET ProPharma Appoints Adrian Pencak as Chief Commercial Officer
spans both full-service outsourcing and Functional Service Provider (FSP) models, with a strong track record of supporting leading pharmaceutical, biotechnology, and life sciences organizations through complex development and commercialization initiatives."Adrian brings deep commercial leadership
More news about: ProPharma Group Holdings LLC
May 27, 2026, 08:34 ET Thomas Scientific Celebrates 125 Years of Advancing Scientific Discovery
States through every major era of scientific advancement — from the early days of analytical chemistry and microbiology to today's frontier work in biotechnology, genomics, and advanced manufacturing. Through organic growth and targeted acquisitions, the company has expanded its portfolio and expertise into
More news about: Thomas Scientific, LLC
May 27, 2026, 08:31 ET MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin
More news about: MetaVia Inc.
May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Evergreen Therapeutics, Alkeus Pharmaceuticals, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences,
More news about: DelveInsight Business Research, LLP
May 27, 2026, 08:11 ET Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
satellites, defense platforms, and space-based AI systems that depend on hardware capable of operating reliably in space. The Company's legacy biotechnology programs will continue to be advanced under a wholly owned subsidiary.Why Space, and Why NowThe commercial space
More news about: Hoth Therapeutics, Inc.
May 27, 2026, 08:08 ET SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies
potential as an MSA-specific CSF biomarker and a molecular classification tool for synucleinopathies.SynuSight Biotech is a clinical-stage biotechnology company dedicated to innovative pipeline development for neurodegenerative diseases, with a long-term focus on the development and clinical translation
More news about: SynuSight Biotech
May 27, 2026, 08:05 ET Rigel to Present at the Jefferies Global Healthcare Conference
Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company
More news about: Rigel Pharmaceuticals, Inc.
May 27, 2026, 08:02 ET Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 27, 2026, 08:00 ET Q32 Bio Announces $55 Million Private Placement Financing
Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
May 27, 2026, 08:00 ET TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities
and more. Founded in 2022 and built on the scientific foundation of Washington University in St. Louis, Panome Bio partners with pharmaceutical, biotechnology, and academic research organizations to accelerate discovery across oncology, neuroscience, immunology and beyond. Learn more at panomebio.com.About
More news about: Panome Bio
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
the Greater China territory from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China's NMPA granted elebsiran Breakthrough Therapy Designation.About Brii BioBrii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to improve
More news about: Brii Biosciences Limited
May 27, 2026, 07:00 ET 騰盛博藥在EASL 2026發布ENSURE II期研究最新突破性數據，進一步支持BRII‑179對實現乙肝病毒持久免疫學控制的潛在作用
iRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的采用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。2024年5月，中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）授予elebsiran突破性療法認定。關於騰盛博藥騰盛博藥（股票代碼：2137.HK）是一家生物技術
More news about: 騰盛博藥生物科技有限公司
May 27, 2026, 07:00 ET Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due
More news about: Nanoscope Therapeutics
May 27, 2026, 06:30 ET Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished biopharmaceutical
More news about: Immunic, Inc.
May 27, 2026, 03:00 ET ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)
VALENCIA, Spain, May 27, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced multiple presentations at the 15th International Myotonic
More news about: ARTHEx Biotech
May 26, 2026, 13:51 ET North Carolina Community College System Announces Search For Next President
education with the needs of a rapidly changing economy, and help position North Carolina as the national leader in workforce talent."From biotechnology and healthcare to advanced manufacturing and technology, the system works alongside employers across North Carolina to build talent pipelines for
More news about: North Carolina Community College System
May 26, 2026, 12:19 ET Rubin Rudman Adds Joshua Caswell as a Partner in Trusts & Estates Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
May 26, 2026, 11:11 ET Solvents Market to Reach US$ 58.1 Bn by 2033 Expands Amid Industrial Demand and Green Chemistry Innovation - Persistence Market Research
Formulation, Cleaning and Purification, Research & Development (R&D), Others), End-User (Pharmaceutical Companies, Generic Drug Manufacturers, Biotechnology Companies, Contract Research Organizations (CROs)), and Regional Analysis for 2026-2033
More news about: Persistence Market Research Pvt. Ltd.
May 26, 2026, 11:00 ET bitBiome Closes Oversubscribed Seed Extension Round
the company's growth through this investment," said Kazuaki Konno, Partner of Darwin Ventures.About bitBiomebitBiome is a biotechnology company unlocking the full potential of our planet's microbes to power the future of the bioeconomy. bitBiome's platform is built on their proprietary
More news about: bitBiome
May 26, 2026, 09:41 ET Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly launched company established by Human Longevity, Inc. today announced a multi-million-dollar
More news about: Insilico Medicine